John Zwetchkenbaum, MD
Allergy · Providence, RINPI 1124027552
Payments from drug & device makers
Across 379 payments — averaging $3733.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$406K
- Regeneron$310K
- Cipla USA Inc.$206K
- Merck$136K
- Hikma Pharmaceuticals USA$73K
- AstraZeneca$43K
- plus $240K from 27 others
Across 8 payments — averaging $170.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$1K
What the payments were for
- Speaking & faculty fees$192,92098%
- Travel & lodging$2,1171%
- Food & beverage$2,3671%
- Education$540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 101 | $406,097 |
| Regeneron | 53 | $310,250 |
| Cipla USA Inc. | 9 | $206,350 |
| Merck | 61 | $136,494 |
| Hikma Pharmaceuticals USA | 9 | $72,895 |
| AstraZeneca | 20 | $42,751 |
| Genentech, Inc. | 5 | $34,284 |
| Shionogi Inc | 16 | $33,973 |
| Teva Pharmaceuticals USA, Inc. | 8 | $33,625 |
| AbbVie | 16 | $32,399 |
| Novartis | 18 | $29,907 |
| Eli Lilly | 4 | $24,690 |
| Astrazeneca UK Limited | 2 | $20,842 |
| Roche Products Limited | 7 | $17,676 |
| Sanofi US Services Inc. | 1 | $10,000 |
| Alk-abello, Inc | 10 | $1,812 |
| Octapharma USA, Inc. | 7 | $143 |
| Sanofi | 2 | $125 |
| Pfizer | 6 | $123 |
| Gilead | 1 | $110 |
| Pharming Healthcare, Inc. | 4 | $73 |
| Genentech USA, Inc. | 4 | $65 |
| CSL Behring | 2 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $47 |
| Boehringer Ingelheim | 2 | $39 |
| Paratek Pharmaceuticals, Inc. | 1 | $27 |
| Organon | 1 | $25 |
| Grifols USA, LLC | 1 | $21 |
| Amgen | 1 | $21 |
| Galderma Laboratories, L.p. | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Arcutis Biotherapeutics, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Dust mite (D. farinae)$1,553
- FASENRA$110
- Epclusa$110
How this compares
Too few allergy providers in Rhode Islandto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 171 | $136,098 |
| Dupixent SyringeDupilumab | 13 | $53,699 |
| Breo ElliptaFluticasone/Vilanterol | 91 | $51,624 |
| XolairOmalizumab | 16 | $43,220 |
| Arnuity ElliptaFluticasone Furoate | 96 | $24,236 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 59 | $18,616 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $18,039 |
| Advair HfaFluticasone Propion/Salmeterol | 41 | $16,547 |
| Qvar RedihalerBeclomethasone Dipropionate | 36 | $13,854 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $9,752 |
| AlvescoCiclesonide | 21 | $7,360 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $6,309 |
| Pulmicort FlexhalerBudesonide | 24 | $6,218 |
| Wixela InhubFluticasone Propion/Salmeterol | 66 | $6,048 |
| Epinephrine | 38 | $5,317 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta | $406,097 | $221,712372 claims |
| Genentech, Inc.Xolair | $34,284 | $43,22016 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $42,751 | $30,56661 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $33,625 | $13,85436 claims |
| Hikma Pharmaceuticals USAEpinephrine | $72,895 | $5,31738 claims |
| MerckAsmanex | $136,494 | $1,22911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Rhode Islandon file to place this against a meaningful peer group, so we don't.
Other allergy in Providence
- Mansi JamesProvidence$810
- Anthony RicciEast Greenwich$9K
- David KatzenWarwick$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.